Lite Strategy LITS
NASDAQ LITS
$1.16 -0.03 (-2.52%)
At close: Oct 23, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Gains from Sales and Divestitures (2024)

Updated

Lite Strategy's Gains from Sales and Divestitures was $500,000 in FY2025 (year ended Jun 30, 2025), compared with -$32,000 in FY2024.

Analysis

Lite Strategy (LITS) Gains from Sales and Divestitures (2024) Analysis & Trends

  • Per Business Quant data, Gains from Sales and Divestitures in earlier fiscal years was -$32,000 in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Lite Strategy 40.43 Mn 8.31 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 500,000.00
Sep 30, 2024 -9,000.00
Jun 30, 2024 -32,000.00
API Access

Lite Strategy Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=LITS&period=max&api_key=YOUR_API_KEY